Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
7 papers
Recent·Most cited
G. Sannier, A. Nicolas, M. Dube, L. Marchitto, M. Nayrac, O. Tastet, A. Tauzin, R. Lima-Barbosa, M. Laporte, R. Cloutier, A. S. Flores, M. Boutin, S. Y. Gong, M. Benlarbi, S. Ding, , D. E. Kaufmann
bioRxiv · Sep 5, 2022Immunology
A. Nicolas, G. Sannier, M. Dube, M. Nayrac, M. M. Painter, R. R. Goel, M. Laporte, H. R. Medjahed, J. Williams, N. Brassard, J. Niessl, L. Gokool, C. Morrisseau, P. Arlotto, C. Tremblay, , D. E. Kaufmann
This study shows that a longer interval between SARS-CoV-2 mRNA vaccine doses enhances B cell responses but has minimal impact on T cell immunity.
bioRxiv · Aug 3, 2022 · PreprintImmunology
D. Chatterjee, A. Tauzin, L. Marchitto, S. Y. Gong, M. Boutin, C. Bourassa, G. Beaudoin-Bussieres, Y. Bo, S. Ding, A. Laumaea, D. Vezina, J. Perreault, L. Gokool, C. Morrisseau, P. Arlotto, , A. Finzi
This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.
bioRxiv · Dec 21, 2021Microbiology
M. Nayrac, M. Dube, G. Sannier, A. Nicolas, L. Marchitto, O. Tastet, A. Tauzin, N. Brassard, G. Beaudoin-Bussieres, D. Vezina, S. Y. Gong, M. Benlarbi, R. Gasser, A. Laumaea, C. Bourassa, , D. E. Kaufmann
The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.
bioRxiv · Dec 18, 2021Immunology
L. Nault, L. Marchitto, G. Goyette, D. Tremblay-Sher, C. Fortin, V. Martel-Laferriere, B. Trottier, J. Richard, M. Durand, D. E. Kaufmann, A. Finzi, C. Tremblay
This study evaluates mRNA vaccine immunogenicity in HIV-positive individuals, finding similar anti-RBD IgG responses to controls in those with CD4 counts >250 cells/mm3, but significantly lower responses in those with <250 cells/mm3.
bioRxiv · Aug 13, 2021Immunology
A. Tauzin, M. Nayrac, M. Benlarbi, S. Y. Gong, R. Gasser, G. Beaudoin-Bussieres, N. Brassard, A. Laumaea, D. Vezina, J. Prevost, S. P. Anand, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, , A. Finzi
This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.
bioRxiv · Mar 18, 2021 · PreprintImmunology
S. P. Anand, J. Prevost, M. Nayrac, G. Beaudoin-Bussieres, M. Benlarbi, R. Gasser, N. Brassard, A. Laumaea, S. Y. Gong, C. Bourassa, E. Brunet-Ratnasingham, H. Medjahed, G. Gendron-Lepage, G. Goyette, L. Gokool, , A. Finzi
This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.
bioRxiv · Jan 25, 2021Microbiology